A Smartphone-Based Intervention to Improve Colorectal Cancer Screening in African American Men
Part of paid clinical trials in Alexandria, Virginia.
- Sponsor
- ISA Associates, Inc.
- Study ID
- NCT06052202
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 45 Years - 75 Years
- Healthy Volunteers
- Accepted
Interventions
- CRC mHealth — BEHAVIORALParticipants receive text messages that contain information about colorectal cancer and screening. Some text messages include links to videos that are intended to reduce barriers to colorectal cancer screening. Other text messages include links to brief web-based assessments. Responses to assessment questions are used to make sure each man receives only the information relevant to his needs. The main educational content is completed in the first 6 weeks. Additional educational and motivation text messages continue for up to 4 more months if a participant reports not having completed colorectal cancer screening.
- Control — BEHAVIORALParticipants receive text messages that include links to videos and/or brochures developed by the Centers for Disease Control. This information is designed to educate the public about colorectal cancer and motivate screening. Text messages are sent every 2-3 days for 6 weeks.
Study Details
The goal of this clinical trial is to test a new smartphone-based program designed to help African American men get screened for colorectal cancer (CRC). The main question it aims to answer is: ° Are African American men who complete the smartphone-based program more likely to get screened for colorectal cancer than men who do not? Participants will: * Complete a baseline survey asking about their colorectal cancer screening history and their thoughts and beliefs about colorectal cancer and the medical system. * Be randomized to receive the new smartphone-based program or to receive text messages containing colorectal cancer education materials designed by the Centers for Disease Control (CDC). The new program sends text messages with information about colorectal cancer. Some of these text messages have links to videos that try to help men overcome anything that may stand in the way of getting screened. * Complete a follow-up survey 6 months after the baseline survey. This survey will ask the same questions as the baseline survey. * A medical records review will be conducted at 6 months to verify whether participants received a colorectal cancer screening test during the study period. Researchers will compare participants who receive the new smartphone-based program to participants who receive the CDC information. The goal is to see whether the smartphone-based program increasing screening more than standard educational materials available on the internet.
Key Dates
- Start date
- Dec 8, 2023
- Status verified
- Dec 2025
- Primary completion
- May 1, 2025
- Completion
- May 1, 2025
Study Design
- Enrollment
- 128 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SCREENING
Arms
- Experimental: CRC mHealth interventionExperimental group participants will have access to the CRC mHealth intervention.
- Active Comparator: Control EducationControl condition participants will receive information about colorectal cancer and screening developed by the Centers for Disease Control.
Primary Outcome Measure
Percentage of Participants Who Received a Colorectal Cancer Screening Test [ Time Frame: Month 6 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| ISA Associates, Inc. | Alexandria | Virginia | 22314 | - |
Find similar trials in Alexandria, VA
Related Studies
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- Colonoscopy vs Stool Testing for Older Adults With Colon PolypsRecruiting · Dartmouth-Hitchcock Medical Center · Birmingham, Alabama
- A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid TumorsPHASE1 · Recruiting · Hefei TG ImmunoPharma Co., Ltd. · Dallas, Texas